Skip to main content
SpringerLink
Log in

Clinical Use of Somatomedin-1

Yes or No?

  • Leading Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Insulin-like growth factor-I (IGF-I) is a polypeptide of 70 amino acids. The circulatory form of IGF-I is synthesised in the liver. The metabolic activity of IGF-I is regulated by 6 IGF binding proteins, the most important being IGF binding protein-3. IGF-I acts via its own receptor, which resembles that of insulin. It has been demonstrated that the effects of pituitary growth hormone (GH, somatropin) on protein metabolism, including growth and effects on nervous and renal tissue, are mediated by IGF-I, whereas these 2 hormones are antagonistic in their effects on insulin and some aspects of lipid metabolism.

The biosynthesis of recombinant human IGF-I (somatomedin-1) in 1986 enabled the initiation of clinical trials. The most important involves replacement therapy in primary IGF-I deficiency, such as Laron syndrome (primary GH resistance or insensitivity), and in patients who have developed antibodies to human GH. In Laron syndrome, which is characterised by dwarfism, somatomedin-1 stimulates growth and increases muscle and bone mass, as well as normalising blood chemistry. In diabetes mellitus types 1 and 2 (insulin-dependent and non-insulin-dependent), somatomedin-1 increases the sensitivity to insulin and improves glucose utilisation, and may contribute to healing of injured nerve tissue and improve renal function in humans. Adverse effects of somatomedin-1 appear to be related to overdosage. In conclusion, somatomedin-1 is an important hormone which has clinical roles as replacement therapy and other pharmacological therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blundell TL, Humbel RE. Hormone families: pancreatic hormones and homologous growth factors. Nature 1980; 287: 781–7

    Article  PubMed  CAS  Google Scholar 

  2. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769–76

    PubMed  CAS  Google Scholar 

  3. Daughaday WH. Somatomedins: a new look at old questions. In: LeRoith D, Raizada MK, editors. Molecular and cellular biology of insulin growth factors and their receptors. New York: Plenum Press, 1989: 1–4

    Chapter  Google Scholar 

  4. Merimee T, Laron Z. Growth hormone, IGF-I and growth: new views of old concepts. In: Merimee T, Laron Z, editors. Modern endocrinology and diabetes. Vol. 4. London: Freund Publishing House, 1996: 226

    Google Scholar 

  5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev 1995; 16: 3–34

    CAS  Google Scholar 

  6. Zapf J, Gosteli-Peter M, Schmid C. Insulin-like growth factor binding proteins (IGFBPs). In: Merimee T, Laron Z, editors. Modern endocrinology and diabetes. Vol. 4. Growth hormone, IGF-I and growth: new views of old concepts. London: Freund Publishing House, 1996: 45–71

    Google Scholar 

  7. Kaneti H, Silbergeld A, Klinger B, et al. Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein. Eur J Endocrinol 1997; 137: 626–30

    Article  Google Scholar 

  8. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular biology of IGF-I receptor. In: Merimee T, Laron Z, editors. Modern endocrinology and diabetes. Vol. 4. Growth hormone, IGF-I and growth: new views of old concepts. London: Freund Publishing House, 1996: 73–99

    Google Scholar 

  9. Adamo ML. Regulation of insulin-like growth factor I gene expression. Diabetes Rev 1995; 3: 2–27

    Google Scholar 

  10. Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995; 3: 38–61

    Google Scholar 

  11. Silbergeld A, Litwin A, Bruchis S, et al. Insulin-like growth factor (IGF-I) in healthy children, adolescents and adults as determined by a radioimmunoassay specific for the synthetic 53–70 peptide region. Clin Endocrinol 1986; 25: 67–74

    Article  CAS  Google Scholar 

  12. Guler HP, Zapf J, Schmid C, et al. Insulin like growth factors I and II in healthy man: estimations of half lives and production rates. Acta Endocrinol 1989; 121: 753–8

    PubMed  CAS  Google Scholar 

  13. Klinger B, Garty M, Silbergeld A, et al. Elimination characteristics of intravenously administered rIGF-I in Laron type dwarfs (LTD). Dev Pharmacol Ther 1990; 15: 196–9

    PubMed  CAS  Google Scholar 

  14. Silbergeld A, Jaber L, Lilos P, et al. A comparison of IGF-I levels measured by two commercially available radioimmunoassays. Acta Endocrinol 1988; 119: 333–8

    PubMed  CAS  Google Scholar 

  15. Laron Z. Prismatic cases: Laron Syndrome (primary growth hormone resistance): from patient to laboratory to patient. J Clin Endocrinol Metab 1995; 80: 1526–73

    Article  PubMed  CAS  Google Scholar 

  16. Phillips LS, Unterman TG. Somatomedin activity in disorders of nutrition and metabolism. In: Daughaday WH, editor. Clinics in endocrinology and metabolism: tissue growth factors. London: WB Saunders, 1984: 145–89

    Google Scholar 

  17. Walker J, Chaussain JL, Bougneres PF. Growth hormone treatment of children with short stature increases insulin secretion but does not impair glucose disposal. J Clin Endocrinol Metab 1989; 69: 253–8

    Article  PubMed  CAS  Google Scholar 

  18. Laron Z, Klinger B, Erster B, et al. Effects of acute administration of insulin like growth factor I in patients with Laron-type dwarfism. Lancet 1988; 2: 1170–2

    Article  PubMed  CAS  Google Scholar 

  19. Niwa M, Sato Y, Saito Y, et al. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin like growth factor I) and 59Val somatomedin C. Ann NY Acad Sci 1986; 469: 31–52

    Article  PubMed  CAS  Google Scholar 

  20. Laron Z. Somatomedin I in clinical use: facts and potential. Drugs 1993; 45: 1–8

    Article  PubMed  CAS  Google Scholar 

  21. Clemmons DR, Underwood LE. Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 1994; 79: 4–6

    Article  PubMed  CAS  Google Scholar 

  22. Hintz RL. Current and potential therapeutic uses of growth hormone and insulin-like growth factor I. Endocrinol Metab Clin North Am 1996; 25: 759–73

    Article  PubMed  CAS  Google Scholar 

  23. Zapf J. Insulin-like growth factor (IGF)-I: an alternative for growth hormone (GH)? Int Growth Monitor 1996; 6: 2–6

    Google Scholar 

  24. Laron Z. Somatomedin-1 (recombinant insulin-like growth factor-I): clinical pharmacology and potential treatment of endocrine and metabolic disorders. BioDrugs 1999; 11: 55–70

    Article  PubMed  CAS  Google Scholar 

  25. Ranke MB. Treatment of growth hormone resistance. J Pediatr Endocrinol Metab 1999; 12 Suppl. 1: 259–266

    PubMed  Google Scholar 

  26. Laron Z, Pertzelan A, Karp M, et al. Laron syndrome — a unique model of IGF-I deficiency. In: Laron Z, Parks JS, editors. Pediatric and adolescent endocrinology. Vol. 24. Lessons from Laron syndrome (LS) 1966–1992 — a model of GH and IGF-I action and interaction. Basel: Karger, 1993: 3–23

    Google Scholar 

  27. Woods KA, Savage MO. Laron syndrome: typical and atypical forms. Ballieres Clin Endocrinol Metab 1996; 10: 371–87

    Article  CAS  Google Scholar 

  28. Laron Z, Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor treatment. Horm Res 1993; 40: 16–22

    Article  PubMed  CAS  Google Scholar 

  29. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol 1994; 41: 631–8

    Article  CAS  Google Scholar 

  30. Dunger DB, Acerini CL, Cheetham TD, et al. How does rhIGF-I replacement improve insulin sensitivity in insulin dependent diabetes mellitus? J Pediatr Endocrinol Metab 1997; 10 Suppl. 1: 117–22

    Google Scholar 

  31. Acerini CL, Patton CM, Savage MO, et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199–204

    Article  PubMed  CAS  Google Scholar 

  32. Zenobi PD, Glatz Y, Keller A, et al. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994; 131:251–7

    Article  PubMed  CAS  Google Scholar 

  33. Moses AC, Young SCJ, Morrow LA, et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45: 91–100

    Article  PubMed  CAS  Google Scholar 

  34. Moses AC. Recombinant human insulin-like growth factor as a therapeutic agent for severe insulin resistance and type II diabetes mellitus. J Pediatr Endocrinol Metab 1997; 10 Suppl. 1: 123–30

    Google Scholar 

  35. Hussain MA, Froesch ER. Treatment of type A insulin resistance with insulin-like growth factor I. Lancet 1993; 341: 1536–7

    Article  PubMed  CAS  Google Scholar 

  36. Morrow LA, O’Brien MB, Moller DE, et al. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994; 79: 205–10

    Article  PubMed  CAS  Google Scholar 

  37. Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42: 696–705

    Article  PubMed  CAS  Google Scholar 

  38. The role of insulin-like growth factors in the nervous system. In: Raizada MK, Le Roith DL, editors. Annals of the New York Academy of Sciences Vol. 692. New York: The New York Academy of Sciences, 1993: 1–336

  39. Galatzer A, Aran O, Nagelberg N, et al. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laron Z, Parks JS, editors. Pediatric and adolescent endocrinology. Vol. 24. Lessons from Laron syndrome (LS) 1966–1992 — a model of GH and IGF-I action and interaction. Basel: Karger, 1993: 53–60

    Google Scholar 

  40. Laron Z, Anin S, Klipper-Aubach Y, et al. Effects of insulin-like growth factor on linear growth, head circumference and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258–61

    Article  PubMed  CAS  Google Scholar 

  41. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. Neurology 1997; 49: 1621–30

    Article  PubMed  CAS  Google Scholar 

  42. Krentz AJ, Koster FT, Crist DM, et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993; 6: 245–51

    PubMed  CAS  Google Scholar 

  43. Laron Z, Wang XL, Silbergeld A, et al. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol 1997; 136: 377–81

    Article  PubMed  CAS  Google Scholar 

  44. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease [review]. Atherosclerosis 1994; 108: 111–26

    Article  PubMed  CAS  Google Scholar 

  45. Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol 1998; 48: 81–7

    Article  CAS  Google Scholar 

  46. Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998; 138: 176–80

    Article  PubMed  CAS  Google Scholar 

  47. Resnicoff M, Burgaud JL, Rotman HL, et al. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 1995; 55: 3739–41

    PubMed  CAS  Google Scholar 

  48. Wolf E, Jehle PM, Weber MM, et al. Human insulin-like growth factor I (IGF-I) produced in the mammary glands of transgenic rabbits: yield, receptor binding, mitogenic activity, and effects on IGF-I binding proteins. Endocrinology 1997; 138: 307–13

    Article  PubMed  CAS  Google Scholar 

  49. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the Noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998; 35: 165–77

    Article  PubMed  CAS  Google Scholar 

  50. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulinlike growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–6

    Article  PubMed  CAS  Google Scholar 

  51. Shimoda N, Tashiro T, Yamamori H, et al. Effects of growth hormone and insulin-like growth factor-I on protein metabolism, gut morphology, and cell-mediated immunity in burned rats. Nutrition 1997; 13: 540–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology and Diabetes Research Unit, Schneider Children’s Medical Center of Israel, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Zvi Laron

Authors
  1. Zvi Laron
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laron, Z. Clinical Use of Somatomedin-1. Pediatr-Drugs 1, 155–159 (1999). https://doi.org/10.2165/00128072-199901030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-199901030-00001

Keywords

Search

Navigation